Besides, we have shown that dasatinib treatment reduces CCR1 expression on late OC precursors (Figure 7B), which is the major receptor for CCL3 (MIP-1α), a crucial stimulator of osteoclastogenesis and of OC function in MM [51], [52]. The gene discussed is CCL3; the disease is Miyoshi myopathy.